Market Overview

UPDATE: Canaccord Downgrades B/E Aerospace


In a research note released Wednesday, Canaccord analyst Ken Herbert downgraded B/E Aerospace (NASDAQ: BEAV) to Hold from Buy and decreased the price target from $100 to $98.

The primary reason for the downgrade was due to the analyst not believing that a sale of the entire company would happen. The firm came to this conclusion after the company announced that it would be separating the company into two primary segments, manufacturing and distribution. The company plans to initiate this in the first quarter of 2015.

The analyst continued to state that even though the company raised its 2014 EPS estimates to $4.35, it still has reason to believe that the stock will face pressure as details of the spinoff emerge. Additionally, the analyst is maintaining his 2014 and 2015 EPS estimates of $4.46 and $5.13, respectively.

As for the price target, a valuation of above 100 requires high multiples, which the company does not possess at this time.

Shares of the company are down less than one percent on Wednesday and are up seven percent year-to-date.

Latest Ratings for BEAV

Nov 2016DowngradesBuyHold
Oct 2016Initiates Coverage OnHold
Oct 2016DowngradesOutperformNeutral

View More Analyst Ratings for BEAV
View the Latest Analyst Ratings

Posted-In: Canaccord Ken HerbertAnalyst Color Downgrades Price Target Analyst Ratings


Related Articles (BEAV)

View Comments and Join the Discussion!

Latest Ratings

TOLGoldman SachsInitiates Coverage On42.0
KBHGoldman SachsInitiates Coverage On36.0
YEXTSunTrust Robinson HumphreyMaintains28.0
LHCGSunTrust Robinson HumphreyMaintains160.0
DLRSunTrust Robinson HumphreyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Takeover Whispers Add To Achillion Pharmaceuticals' Momentum

UPDATE: Praesidium Issues Letter to TIBCO Board, Looking to Actively Engage Board, Seeking Exploration of Value